Cargando…
Five-year follow-up study of stage I-IV rectal cancer including EGFR immunoexpression and p21 immunoactivity
INTRODUCTION: Both environmental and genetic factors increase the likelihood of developing rectal cancer. AIM: To assess the EGFR and p21 immunoreactivity in rectal cancer and to assess its relationship with the clinical outcome. MATERIAL AND METHODS: Applying exclusion criteria, 102 patients with s...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690949/ https://www.ncbi.nlm.nih.gov/pubmed/34976241 http://dx.doi.org/10.5114/pg.2021.104980 |
_version_ | 1784618710993993728 |
---|---|
author | Kozłowska-Geller, Monika Głuszek, Stanisław Lewitowicz, Piotr |
author_facet | Kozłowska-Geller, Monika Głuszek, Stanisław Lewitowicz, Piotr |
author_sort | Kozłowska-Geller, Monika |
collection | PubMed |
description | INTRODUCTION: Both environmental and genetic factors increase the likelihood of developing rectal cancer. AIM: To assess the EGFR and p21 immunoreactivity in rectal cancer and to assess its relationship with the clinical outcome. MATERIAL AND METHODS: Applying exclusion criteria, 102 patients with stage I–IV rectal cancer, who had undergone scheduled surgery during the period 2005–2011, were included in the study. There was a follow-up study with a span of 5 years from the date of the surgery. Immunohistochemistry using epidermal growth factor receptor (EGFR Ab10, Clone111.6) and antibodies against p21 (p21(WAF1) (Clone H252)) was performed to detect overexpression of the targeted receptor. Digital analysis of positive reactions of membranes and nuclei was performed utilizing Visiopharm. RESULTS: The degree of EGFR intensity (log OR = 0.854, OR = 2.35, 95% CI: 1.14–4.85, p = 0.021) is a significant factor in the prognosis of death within 2 years after surgery. The OS curve showed a significant decrease after 40 months from the date of surgery in the cases where EGFR had high expression. The ROC curve for cancer stage, according to the UICC classification and EGFR expression, in order to predict 2-year RFS, reached a high specificity value (ROC = 0.81, p = 0.0408). The analysis showed no statistically significant differences in the survival curves of patients in groups with immunoreactivity of p21 protein at 0, 1, 2, 3 (p = 0.6453 in the log-rank test). Also, it is not a significant risk factor for death (HR = 0.915, p = 0.7842) or for tumor dissemination (HR = 0.94, p = 0.9426). CONCLUSIONS: The determination of EGFR immunoreactivity is important in the monitoring and treatment of patients with rectal cancer, as opposed to p21. |
format | Online Article Text |
id | pubmed-8690949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-86909492021-12-30 Five-year follow-up study of stage I-IV rectal cancer including EGFR immunoexpression and p21 immunoactivity Kozłowska-Geller, Monika Głuszek, Stanisław Lewitowicz, Piotr Prz Gastroenterol Original Paper INTRODUCTION: Both environmental and genetic factors increase the likelihood of developing rectal cancer. AIM: To assess the EGFR and p21 immunoreactivity in rectal cancer and to assess its relationship with the clinical outcome. MATERIAL AND METHODS: Applying exclusion criteria, 102 patients with stage I–IV rectal cancer, who had undergone scheduled surgery during the period 2005–2011, were included in the study. There was a follow-up study with a span of 5 years from the date of the surgery. Immunohistochemistry using epidermal growth factor receptor (EGFR Ab10, Clone111.6) and antibodies against p21 (p21(WAF1) (Clone H252)) was performed to detect overexpression of the targeted receptor. Digital analysis of positive reactions of membranes and nuclei was performed utilizing Visiopharm. RESULTS: The degree of EGFR intensity (log OR = 0.854, OR = 2.35, 95% CI: 1.14–4.85, p = 0.021) is a significant factor in the prognosis of death within 2 years after surgery. The OS curve showed a significant decrease after 40 months from the date of surgery in the cases where EGFR had high expression. The ROC curve for cancer stage, according to the UICC classification and EGFR expression, in order to predict 2-year RFS, reached a high specificity value (ROC = 0.81, p = 0.0408). The analysis showed no statistically significant differences in the survival curves of patients in groups with immunoreactivity of p21 protein at 0, 1, 2, 3 (p = 0.6453 in the log-rank test). Also, it is not a significant risk factor for death (HR = 0.915, p = 0.7842) or for tumor dissemination (HR = 0.94, p = 0.9426). CONCLUSIONS: The determination of EGFR immunoreactivity is important in the monitoring and treatment of patients with rectal cancer, as opposed to p21. Termedia Publishing House 2021-03-31 2021 /pmc/articles/PMC8690949/ /pubmed/34976241 http://dx.doi.org/10.5114/pg.2021.104980 Text en Copyright © 2021 Termedia https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) ) |
spellingShingle | Original Paper Kozłowska-Geller, Monika Głuszek, Stanisław Lewitowicz, Piotr Five-year follow-up study of stage I-IV rectal cancer including EGFR immunoexpression and p21 immunoactivity |
title | Five-year follow-up study of stage I-IV rectal cancer including EGFR immunoexpression and p21 immunoactivity |
title_full | Five-year follow-up study of stage I-IV rectal cancer including EGFR immunoexpression and p21 immunoactivity |
title_fullStr | Five-year follow-up study of stage I-IV rectal cancer including EGFR immunoexpression and p21 immunoactivity |
title_full_unstemmed | Five-year follow-up study of stage I-IV rectal cancer including EGFR immunoexpression and p21 immunoactivity |
title_short | Five-year follow-up study of stage I-IV rectal cancer including EGFR immunoexpression and p21 immunoactivity |
title_sort | five-year follow-up study of stage i-iv rectal cancer including egfr immunoexpression and p21 immunoactivity |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690949/ https://www.ncbi.nlm.nih.gov/pubmed/34976241 http://dx.doi.org/10.5114/pg.2021.104980 |
work_keys_str_mv | AT kozłowskagellermonika fiveyearfollowupstudyofstageiivrectalcancerincludingegfrimmunoexpressionandp21immunoactivity AT głuszekstanisław fiveyearfollowupstudyofstageiivrectalcancerincludingegfrimmunoexpressionandp21immunoactivity AT lewitowiczpiotr fiveyearfollowupstudyofstageiivrectalcancerincludingegfrimmunoexpressionandp21immunoactivity |